阿诺医药(Adlai Nortye)近日宣布,已与Ask Pharm就其泛Ras(on)抑制剂AN9025在大中华区达成独家授权协议。该协议的签署标志着双方在创新肿瘤治疗领域的战略合作迈出重要一步。
阿诺医药(Adlai Nortye)近日宣布,已与Ask Pharm就其泛Ras(on)抑制剂AN9025在大中华区达成独家授权协议。该协议的签署标志着双方在创新肿瘤治疗领域的战略合作迈出重要一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.